Comparison of Therapy Augmentation and Deviation Rates from the Recommended Once-Daily Dosing Regimen between LDX and Commonly Prescribed Long-Acting Stimulants for the Treatment of ADHD in Youth and Adults.

Comparison of Therapy Augmentation and Deviation Rates from the Recommended Once-Daily Dosing Regimen between LDX and Commonly Prescribed Long-Acting Stimulants for the Treatment of ADHD in Youth and Adults.

J Med Econ. 2013 Aug 13;

Authors: Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu E, Haim Erder M

Abstract
Abstract Objective: To compare therapy augmentation and deviation rates from the recommended once-daily dosing regimen in ADHD patients initiated on Lisdexamfetamine (LDX) vs. other once-daily FDA-approved stimulants. Methods: ADHD patients initiated on a long-acting ADHD stimulant medication (index medication) in/after 2007 were selected from a large US administrative claims database. Patients were required to be persistent for ≥90 days and continuously enrolled in their healthcare plan for ≥12 months following treatment initiation date. Based on age and previous treatment status, patients were classified into treatment-naïve children and adolescents (6-17 years old), previously treated children and adolescents, treatment-naïve adults (≥18 years old), and previously treated adults. Furthermore, patients were classified into four mutually exclusive treatment groups, based on index medication: LDX, OROS MPH, other methylphenidate/dexmethylphenidate long-acting (MPH LA), and amphetamine/dextroamphetamine long-acting (AMPH LA). The average daily consumption was measured as the quantity of index medication supplied in the 12-month study period divided by the total number of days of supply. Therapy augmentation was defined as the use of another ADHD medication concomitantly with the index medication for ≥28 consecutive days. Therapy augmentation and deviation rates from the recommended once-daily dosing regimen were compared between treatment groups using multivariate logistic regression models. Results: Compared to each other treatment groups, LDX patients were less likely to augment with another ADHD medication (range odds ratios [OR]; 1.28-3.30) and to deviate from the recommended once-daily dosing regimen (range OR; 1.73-4.55),except for previously treated adult patients, where therapy augmentation differences were not statistically significant when compared to OROS MPH and MPH LA patients. Limitation: This study did not control for ADHD severity. Conclusion: Overall, compared to LDX-treated patients, patients initiated on other ADHD medications were equally or more likely to have a therapy augmentation and more likely to deviate from the recommended once-daily dosing regimen.

PMID: 23937642 [PubMed – as supplied by publisher]

via http://www.ncbi.nlm.nih.gov/pubmed/23937642?dopt=Abstract